These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 32376370)

  • 41. RNA aptamer-conjugated liposome as an efficient anticancer drug delivery vehicle targeting cancer cells in vivo.
    Baek SE; Lee KH; Park YS; Oh DK; Oh S; Kim KS; Kim DE
    J Control Release; 2014 Dec; 196():234-42. PubMed ID: 25450401
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Failure of active targeting by a cholesterol-anchored ligand and improvement by altering the lipid composition to prevent ligand desorption.
    Yamamoto S; Sakurai Y; Harashima H
    Int J Pharm; 2018 Jan; 536(1):42-49. PubMed ID: 29126905
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Liposome-based glioma targeted drug delivery enabled by stable peptide ligands.
    Wei X; Gao J; Zhan C; Xie C; Chai Z; Ran D; Ying M; Zheng P; Lu W
    J Control Release; 2015 Nov; 218():13-21. PubMed ID: 26428462
    [TBL] [Abstract][Full Text] [Related]  

  • 44. In vivo study of doxorubicin-loaded cell-penetrating peptide-modified pH-sensitive liposomes: biocompatibility, bio-distribution, and pharmacodynamics in BALB/c nude mice bearing human breast tumors.
    Ding Y; Cui W; Sun D; Wang GL; Hei Y; Meng S; Chen JH; Xie Y; Wang ZQ
    Drug Des Devel Ther; 2017; 11():3105-3117. PubMed ID: 29123382
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Sequential treatment of drug-resistant tumors with RGD-modified liposomes containing siRNA or doxorubicin.
    Jiang J; Yang SJ; Wang JC; Yang LJ; Xu ZZ; Yang T; Liu XY; Zhang Q
    Eur J Pharm Biopharm; 2010 Oct; 76(2):170-8. PubMed ID: 20600887
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Lactoferrin-modified PEGylated liposomes loaded with doxorubicin for targeting delivery to hepatocellular carcinoma.
    Wei M; Guo X; Tu L; Zou Q; Li Q; Tang C; Chen B; Xu Y; Wu C
    Int J Nanomedicine; 2015; 10():5123-37. PubMed ID: 26316745
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Development of synthetic peptide-modified liposomes with LDL receptor targeting capacity and improved anticancer activity.
    Liu M; Li W; Larregieu CA; Cheng M; Yan B; Chu T; Li H; Mao SJ
    Mol Pharm; 2014 Jul; 11(7):2305-12. PubMed ID: 24830852
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Phytosterol-loaded CD44 receptor-targeted PEGylated nano-hybrid phyto-liposomes for synergistic chemotherapy.
    Gautam M; Thapa RK; Gupta B; Soe ZC; Ou W; Poudel K; Jin SG; Choi HG; Yong CS; Kim JO
    Expert Opin Drug Deliv; 2020 Mar; 17(3):423-434. PubMed ID: 32028805
    [No Abstract]   [Full Text] [Related]  

  • 49. Liposomes, modified with PTD(HIV-1) peptide, containing epirubicin and celecoxib, to target vasculogenic mimicry channels in invasive breast cancer.
    Ju RJ; Li XT; Shi JF; Li XY; Sun MG; Zeng F; Zhou J; Liu L; Zhang CX; Zhao WY; Lu WL
    Biomaterials; 2014 Aug; 35(26):7610-21. PubMed ID: 24912818
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Chitooligosaccharides Modified Reduction-Sensitive Liposomes: Enhanced Cytoplasmic Drug Delivery and Osteosarcomas-Tumor Inhibition in Animal Models.
    Yin X; Chi Y; Guo C; Feng S; Liu J; Sun K; Wu Z
    Pharm Res; 2017 Oct; 34(10):2172-2184. PubMed ID: 28726003
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Lipopepsomes: A novel and robust family of nano-vesicles capable of highly efficient encapsulation and tumor-targeted delivery of doxorubicin hydrochloride in vivo.
    Qiu M; Sun H; Meng F; Cheng R; Zhang J; Deng C; Zhong Z
    J Control Release; 2018 Feb; 272():107-113. PubMed ID: 29355618
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Redox responsive liposomal nanohybrid cerasomes for intracellular drug delivery.
    Zhou G; Li L; Xing J; Jalde S; Li Y; Cai J; Chen J; Liu P; Gu N; Ji M
    Colloids Surf B Biointerfaces; 2016 Dec; 148():518-525. PubMed ID: 27690240
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Hydrophobic penetrating peptide PFVYLI-modified stealth liposomes for doxorubicin delivery in breast cancer therapy.
    Cai D; Gao W; He B; Dai W; Zhang H; Wang X; Wang J; Zhang X; Zhang Q
    Biomaterials; 2014 Feb; 35(7):2283-94. PubMed ID: 24360410
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Improving breast cancer therapy using doxorubicin loaded solid lipid nanoparticles: Synthesis of a novel arginine-glycine-aspartic tripeptide conjugated, pH sensitive lipid and evaluation of the nanomedicine in vitro and in vivo.
    Zheng G; Zheng M; Yang B; Fu H; Li Y
    Biomed Pharmacother; 2019 Aug; 116():109006. PubMed ID: 31152925
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Selenium-functionalized liposomes for systemic delivery of doxorubicin with enhanced pharmacokinetics and anticancer effect.
    Xie Q; Deng W; Yuan X; Wang H; Ma Z; Wu B; Zhang X
    Eur J Pharm Biopharm; 2018 Jan; 122():87-95. PubMed ID: 29032193
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Robust, tumor-homing and redox-sensitive polymersomal doxorubicin: A superior alternative to Doxil and Caelyx?
    Zou Y; Meng F; Deng C; Zhong Z
    J Control Release; 2016 Oct; 239():149-58. PubMed ID: 27569664
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Improved drug delivery and therapeutic efficacy of PEgylated liposomal doxorubicin by targeting anti-HER2 peptide in murine breast tumor model.
    Zahmatkeshan M; Gheybi F; Rezayat SM; Jaafari MR
    Eur J Pharm Sci; 2016 Apr; 86():125-35. PubMed ID: 26972276
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Delivery of hydrophilic drug doxorubicin hydrochloride-targeted liver using apoAI as carrier.
    Yuan Y; Wang W; Wang B; Zhu H; Zhang B; Feng M
    J Drug Target; 2013 May; 21(4):367-74. PubMed ID: 23600747
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Tumor-targeted liposomal drug delivery mediated by a diseleno bond-stabilized cyclic peptide.
    Li C; Wang Y; Zhang X; Deng L; Zhang Y; Chen Z
    Int J Nanomedicine; 2013; 8():1051-62. PubMed ID: 23515368
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Co-delivery of baicalein and doxorubicin by hyaluronic acid decorated nanostructured lipid carriers for breast cancer therapy.
    Liu Q; Li J; Pu G; Zhang F; Liu H; Zhang Y
    Drug Deliv; 2016 May; 23(4):1364-8. PubMed ID: 25874959
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.